MT1 can be used for melanotan I or for a melatonin receptor, so the label is too ambiguous for a health claim.
Do not confuse MT1 with melatonin or assume that it means melanotan I.
MT1 is ambiguous. It might refer to melanotan I or to a melatonin receptor, which are not the same thing.
Reported benefits, not product promises
Personal stories are anecdotal. They cannot show whether a product caused a change, how often it happens or what the risks are.
Neither reading can be assumed from MT1 alone. Evidence for named afamelanotide medicine in a rare light-sensitive condition is not evidence for tanning, sleep, or an unidentified MT1 product.
MT1 is ambiguous. In receptor research it usually means the melatonin MT1 receptor. In product marketing it may be used loosely for melanotan I, also called afamelanotide, an alpha-melanocyte-stimulating hormone analogue. These are not the same substance or evidence base.
In 2015, two randomised, double-blind trials enrolled 74 European and 94 US patients with erythropoietic protoporphyria, a rare condition that causes painful reactions to sunlight. Median pain-free sunlight exposure was longer with afamelanotide than placebo in both trials. This concerns confirmed afamelanotide in people with this rare condition, not a tanning or wellness claim.
Afamelanotide for erythropoietic protoporphyria (2015)The FDA approved Scenesse, containing afamelanotide, in 2019 to increase pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria. This is a named medicine and indication, not evidence for an item identified only as MT1.
FDA orphan-drug approval record for Scenesse (2019)Do not assume MT1 means either melanotan I or a melatonin-related product without a full label. The approval and trial evidence above do not transfer between those meanings or to an unverified item.
There is no reliable way to assign a benefit or research topic until the ingredient is confirmed.
The same shorthand can describe different biological concepts.
The code does not establish which substance is present, or whether it is regulated, correctly labelled or sterile.
This is not a complete list of risks or a personal safety assessment.
Keep its packaging and ingredient information. Check the formulation, instructions and supplies together. An unidentified product cannot be made safe by an online dose calculation.
Before mixing: checks & suppliesMedsafe specifically warns of unapproved peptides and products sold outside regulated supply.
“Research purposes only” is not a legal exemption or a safety guarantee. This guide is for research and educational purposes only and does not recommend taking this substance.
Read Medsafe’s warningThe things you might be wondering.
It might, but the abbreviation alone does not prove it.
No. MT1 can also refer to a melatonin receptor, which is different from a melatonin product.
Different substances have different evidence, risks and regulatory status.
Two perspectives on the wider peptide conversation. These episodes provide context; they do not identify or validate a product with this label. Pick a thumbnail to watch here.
Huberman Lab · 1 April 2024
A useful starting point for the peptide conversation. Andrew Huberman talks through repair-related peptides, growth-hormone pathways and PT-141, alongside sourcing, side effects and the limits of the evidence. Listen for the difference between a promising idea and a result tested in people.
Play loads the YouTube player. Podcast discussion is context, not medical advice.
Huberman Lab · 1 June 2026
Why are peptides getting so much attention? Dr Abud Bakri joins Andrew Huberman to discuss BPC-157, GHK-Cu, melanotan and GLP-1 medicines. They explore what is being studied, why product sourcing matters and where animal findings still need to be tested in humans.
Play loads the YouTube player. Podcast discussion is context, not medical advice.